IV Cisplatin

PreclinicalSmall molecule

UUniversitair Ziekenhuis Brussel

IV Cisplatin is one of 4 small molecule programs targeting Intratumoral Injection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intratumoral InjectionRecruiting

Soft TissueActive, not recruiting

Intratumoral InjectionPreclinical

Recruiting

Soft TissuePreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Soft Tissue

#DrugCompanyPhaseTrials

Hyperbaric Oxygen Treatment

RRestorix Research Institute, LLLP

Phase 3

1 2

IC-Green

PProvepharm SAS

Preclinical

1 3

IV Cisplatin

UUniversitair Ziekenhuis Brussel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Soft Tissue

NCT03707808

Clinical

Trials by Indication[1]

Lymphoma1 trial

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

Withdrawn·NNational Cancer Centre, Singapore·Phase 1·NCT04230330

Soft Tissue1 trial

A Randomized Phase II Clinical Trial on Intratumoral AS01B/Ipilimumab Plus Intravenous Nivolumab With or Without Autologous CD1c(BDCA-1)+ / CD141(BDCA-3)+ Myeloid Dendritic Cells.

Active, not recruiting·UUniversitair Ziekenhuis Brussel·Preclinical·NCT03707808·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IV Cisplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV Cisplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitair Ziekenhuis Brussel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversitair Ziekenhuis Brussel

IV Cisplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lymphoma1 trial

Soft Tissue1 trial

References

Drug Info

Quick Facts

Related News